Menu

CDC, FDA Warn Against Kratom Use

The herbal supplement, deemed an opioid by the FDA, was recently linked to a Salmonella outbreak in 20 states. 

Feb 26, 2018
Jim Daley

FLICKR, FDA

Last Tuesday (February 20), the Centers for Disease Control and Prevention (CDC) issued a recommendation warning consumers to avoid kratom, citing a multistate outbreak of Salmonella that has been linked to the dietary supplement. The US Food and Drug Administration (FDA) followed on Wednesday by announcing a voluntary recall and destruction of kratom supplements sold by the Missouri-based company Divinity Products Distribution.

The Salmonella outbreak began in October, and cases have been documented in 20 states. No deaths have been reported as a result of the outbreak, but eleven individuals have been hospitalized. The CDC used whole genome sequencing to determine that the Salmonella samples from affected people were “closely related,” indicating they probably share a common infection source. Eight of the hospitalized individuals said they had consumed kratom in the form of pills, powder, or tea, the agency says.

In the FDA’s announcement, it cites “serious risks” associated with using kratom, which the agency recently classified as an opioid, and encourages all companies involved in the sale of the supplement to remove their products from the market. “[C]ompounds contained in kratom are opioids and are expected to have similar addictive effects as well as risks of abuse, overdose and, in some cases, death,” FDA Commissioner Scott Gottlieb says in the statement. He adds that there is no evidence indicating the supplement is “safe or effective for any medical use.”

The FDA notes that no recent reports of illness were linked specifically to Divinity Products Distribution’s kratom-containing supplements. However, in addition to the recall and destruction of its existing kratom products, the company has agreed to cease selling them in the future. 

See “FDA Declares Kratom an Opioid. We’re Here to Explain What It Does

The CDC says kratom is an “opioid substitute” that provides stimulant effects to the user. Earlier this month, the FDA announced that based on an evaluation using a computational model of the molecular structure of kratom, the agency felt “confident in calling compounds found in kratom, opioids.”

Advocates for kratom argue that the supplement has clear differences from classic opioids, and that the two substances have distinct user populations. On February 8, scientists from the American Kratom Association sent a letter to the White House stating that “the current body of credible research” shows that kratom is neither addictive nor opioid-like.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.